Search Videos

Multiplexed genomic and proteomic molecular profiling feasible for metastatic breast cancer
137 views | Added Jul 19, 2013 | Rate View top rated
Share this story
PARIS – Emanuel F. Petricoin, PhD, co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University, discusses results from a recent trial presented at ASCO 2013 which demonstrated that patient-specific target driven treatment selection based on molecular profiling of a metastatic lesion provided clinical benefit heavily pretreated metastatic breast cancer.
According to Petricoin, the researchers based their trial on the Bisgrove trial, which evaluated which treatment would be best for a specific tumor type based on molecular profiling. In the study by Petricoin and colleagues, the objective of their prospective pilot study was to determine if treatment selected by molecular profiling of metastatic breast cancer tumors at time of disease progression provides greater clinical benefit than empiric treatment selection.
The primary objective of their study was to compare the PFS using a molecular profiling selected treatment regimen to the preceding regimen. Molecular profiling selected therapy would warrant further investigation if ≥ 35% of the patients demonstrated a PFS ratio of ≥ 1.3.
View more stories like this
Be the first to comment. Please sign in to add your thoughts below.
Related Videos
This collection is currently empty.